Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

UC Health

Neither a doctor nor a teaching hospital

Research payments

$8,806,433

38 payments

Through program year 2024, UC Health is reported as receiving $8,806,433 in research payments, across 38 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $62,366 2
2023 Research $1,295 2
2022 Research $21,175 2
2021 Research $183,145 15
2020 Research $8,517,041 9
2019 Research $21,411 8

Breakdown

Who paid Research payments · program years 2019–2024
  1. AbbVie, Inc. $8,552,547 5 payments
  2. Alexion Pharmaceuticals, Inc. $183,145 15 payments
  3. Roche Products Limited $16,575 1 payment
  4. Pharmacyclics LLC, An AbbVie Company $13,900 3 payments
  5. Catalyst Pharmaceuticals, Inc. $11,983 1 payment
  6. ViiV Healthcare Company $10,723 4 payments
  7. GlaxoSmithKline, LLC. $8,866 1 payment
  8. Stryker Corporation $4,500 1 payment
  9. Allergan Inc. $2,593 4 payments
  10. Incyte Corporation $1,295 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A18-860 $8,502,164 4 payments
  2. A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) $60,444 5 payments
  3. Decreasing Onset to Treatment Times in Anti-Xa Associated Intracranial Hemorrhage (DOAC-ICH): A Prospective Feasibility Study $56,382 1 payment
  4. First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies $50,383 1 payment
  5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis $49,323 5 payments
  6. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) $16,996 4 payments
  7. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $16,575 1 payment
  8. Pcyc-1145-Lt $13,900 3 payments
  9. Long Term Safety Study of Amifampridine Phosphate in Patients With Musk Positive Antibody Positive Myasthenia Gravis Patients $11,983 1 payment
  10. A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $8,866 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record